ArticleBMC cancer2026
Serum amyloid A kinetics predicts outcomes to PD-1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSerum amyloid A (SAA) is an acute-phase responsive protein, and its kinetic changes may be related to the immune therapy response. Therefore, we assume that it can predict the outcomes of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) patients receiving immunotherapy.
methodsWe conducted a retrospective cohort study to analyze the clinical data of 186 patients with RM-NPC who received PD-1 inhibitor therapy. The patients were divided into three groups: the SAA flare-responder group (SAA increased by at least two times compared to baseline and then decreased below baseline), the SAA responder group (SAA decreased by ≥ 30% within three months without a prior flare), and the remaining patients were SAA non-responders. The primary endpoint was progression-free survival (PFS). Secondary endpoints included the objective response rate (ORR), disease control rate (DCR), and overall survival (OS).
resultsThe median PFS (mPFS) of the entire cohort was 3.52 months, and the median OS (mOS) was 17.02 months. The ORR was 24.73% and DCR was 58.60%. Fourteen (7.53%) patients were classified as SAA flare-responders, 95 (51.08%) patients were defined as SAA responders, and 77 (41.40%) as SAA non-responders. The mPFS of the three SAA kinetic groups was 7.47, 3.97, and 1.87 months (p = 0.0008) and the mOS was 31.13, 26.93, and 15.87 months (p = 0.0283). The ORR of the three groups was 35.71%, 33.68%, and 11.69%, respectively (p = 0.0024). The DCR of the three groups was 85.71%, 71.58%, and 37.66%, respectively (p < 0.0001). It is worth noting that SAA kinetics have no predictive value for RM-NPC patients with low EBV DNA levels.
conclusionSAA kinetics can predict the prognosis of RM-NPC patients treated with PD-1 inhibitors, and can reliably differentiate RM-NPC patients most likely to benefit from immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.